✦ LIBER ✦

Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer

✍ Scribed by Siqing Fu; Wei Hu; Revathy Iyer; John J. Kavanagh; Robert L. Coleman; Charles F. Levenback; Anil K. Sood; Judith K. Wolf; David M. Gershenson; Maurie Markman; Bryan T. Hennessy; Razelle Kurzrock; Robert C. Bast Jr

Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 298 KB
Volume: 117
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.25701

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase 1 and pharmacodynamic study of d

A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer

✍ Fang Fang; Curt Balch; Jeanne Schilder; Timothy Breen; Shu Zhang; Changyu Shen; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 412 KB 👁 2 views

## Abstract ## BACKGROUND: Aberrant DNA methylation is a hallmark of cancer, and DNA methyltransferase inhibitors have demonstrated clinical efficacy in hematologic malignancies. On the basis of preclinical studies indicating that hypomethylating agents can reverse platinum resistance in ovarian c

Combined weekly topotecan and biweekly b

Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer : Results of a Phase 2 Study

✍ Kathryn F. McGonigle; Howard G. Muntz; Jacqueline Vuky; Pamela J. Paley; Dan S. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 278 KB

Role of salvage chemotherapy with topote

Role of salvage chemotherapy with topotecan and cisplatin in patients with paclitaxel- and platinum-resistant recurrent ovarian or primary peritoneal cancer: A phase II pilot study

✍ Ghamande, Sharad A.; Piver, M. Steven 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 56 KB 👁 2 views

## Background and Objectives: We assessed the role of salvage chemotherapy with topotecan and cisplatin in patients with platinum-and paclitaxel-resistant advanced and recurrent ovarian or primary peritoneal cancer, based on the reported in vivo and in vitro synergism between these two drugs. Meth